‹ ›
MYP_133525
← PREVIOUS NEXT → BACK
Basic Information
EKL0C
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Standard
49 amino acids
C266H408N58O84S2
Standard
Sequence
SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC
Physicochemical Analysis
5826.55 Da
4.44
-5.53
-5.79
-0.1130
-0.49
0.75
0.00
15.89
93.47
0.1429
12950.00
12950.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
2330.81
-14.26
81.0
81.0
201.0
410.0
8.0
50.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0025604 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical or chemical modification [Modified]
None
Cholesterol conjugation
C-terminal cholesterol conjugation (Chol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 pseudovirus; 293T/ACE2 cells
0.147±0.055 μM
IC50 (pseudovirus entry inhibition)
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
RECORD: Rec_0033796 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical or chemical modification [Modified]
None
Cholesterol conjugation
C-terminal cholesterol conjugation (Chol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 pseudovirus; Caco-2 cells
0.162±0.022 μM
IC50 (pseudovirus entry inhibition)
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
RECORD: Rec_0041797 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical or chemical modification [Modified]
None
Cholesterol conjugation
C-terminal cholesterol conjugation (Chol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 spike-mediated cell-cell fusion
0.021±0.003 μM
IC50 (cell-cell fusion inhibition)
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/
RECORD: Rec_0091472 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical or chemical modification [Modified]
None
Cholesterol conjugation
C-terminal cholesterol conjugation (Chol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 pseudovirus; Huh-7 cells
0.122±0.012 μM
IC50 (pseudovirus entry inhibition)
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/